Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman ...
GlobeNewswire · 07/12 11:00
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19. Roche Holding AG (OTC: RHHBY) and Atea jointly develop AT-527, an oral direct-act...
Benzinga · 06/30 15:11
Thinking about buying stock in Dare Bioscience, Powerbridge Technologies, Atea Pharmaceuticals, Ammo Inc, or Eloxx Pharmaceuticals?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, PBTS, AVIR, POWW, and ELOX.
PR Newswire - PRF · 06/30 13:31
BRIEF-Atea’S At-527 Reduces Viral Replication In Hospitalized Patients With Covid-19 In Phase 2 Interim Analysis · 06/30 11:09
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG (OTC: RHHBY) of $50 million. Under the license agreement, Roche a...
Benzinga · 06/16 13:26
BRIEF-Atea Pharmaceuticals Announces Achievement Of At-527 Development Milestone Under License Agreement With Roche · 06/16 11:09
INSIGHT-Inside the race to find a COVID-19 treatment pill · 05/21 09:57
BRIEF-Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., To Board Of Directors · 05/20 11:18
Atea Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a good week for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders, because the company has just...
Simply Wall St. · 05/15 07:26
Atea Pharmaceuticals Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Atea Pharmaceuticals Inc (NASDAQ:AVIR) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 05/13 18:31
Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss · 05/07 13:12
Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus · 05/07 12:35
Hepatitis C Virus Envelope Protein E2 Market 2021: Comprehensive Size Analysis, In-depth Research on Market Share, Growth Factors, Regions, Business Plans, with Development Status till 2027
May 07, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Our Latest Report on “Hepatitis C Virus...
The Express Wire · 05/07 05:03
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates · 05/06 14:55
Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses · 05/06 14:42
Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales · 05/06 14:39
Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances · 05/06 14:24
Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View · 05/04 16:20
William Blair Thinks Atea Pharmaceuticals’ Stock is Going to Recover
In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Atea Pharmaceuticals (AVIR). The company's shares closed last
SmarterAnalyst · 04/30 20:06
Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has dosed the first patient in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial anticipates enrolling approximately 1,400 non-hospitalized adult...
Benzinga · 04/29 10:44
Webull provides a variety of real-time AVIR stock news. You can receive the latest news about Atea Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AVIR
Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of product candidates to treat coronavirus disease (COVID-19), dengue, chronic hepatitis C (HCV), and respiratory syncytial virus (RSV). Its purine nucleotide prodrug platform develops treatments for life threatening diseases caused by single stranded ribonucleic acid (ssRNA) viral infections. Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients with COVID-19. It is developing AT-752, an oral, purine nucleoside prodrug product candidate for the treatment of dengue. It is also developing AT-787 for the treatment of chronic HCV infection, including patients with decompensated cirrhosis. It is evaluating AT-889 and other candidates for the treatment of RSV.